(Gaithersburg, MD) – August 4, 2020 – Smithers, a leading provider of testing, consulting, information, and compliance services, announces its ability to handle any size study involving COVID-19 or other infectious diseases with associated coagulopathy. There is significant evidence the most common pattern of coagulopathy observed in patients hospitalized with COVID-19 is characterized by elevations in fibrinogen and D-dimer levels which can also be characterized by high levels of complement activation. Also, clinical evidence indicates that other infectious diseases affect hemostasis, such as those involved in sepsis. Smithers has the technology, capacity, and unmatched combination of immunoassay and hematologic assay expertise to support any size clinical study as it relates to the blood and its reaction to these types of diseases.
“Every day the scientific community is learning more about how COVID-19 interacts with and affects hemostasis,” said Ira DuBey, PhD, President, Pharmaceutical Development Services. “Recently, the American Society of Hematology, recommended monitoring platelet count, PT / aPTT, and D-dimer, and fibrinogen. Worsening of these parameters, specifically the D-dimer, indicates progressive severity of COVID-19 infection and predicts that more aggressive critical care will be needed, states Dr. DuBey. “Smithers has the ability to monitor these critical biomarkers for clients developing therapies to combat COVID-19 and other infectious diseases.”
The Smithers Pharmaceutical Development Services division is a specialized, bioanalytical contract research organization (CRO) which provides a comprehensive range of services from discovery through phase IV for the development of large-molecule therapeutics. Smithers has two labs in the United States, located in Gaithersburg, Maryland and Ewing, New Jersey, dedicated to pharmaceutical development.
Smithers continues to invest in talent, technology, and quality assurance to better serve its clients and grow its market share in the life sciences industries, which include pharmaceutical, medical device, and environmental sciences.
Founded in 1925 and headquartered in Akron, Ohio, Smithers is a multinational provider of testing, consulting, information, and compliance services. With laboratories and operations in North America, Europe, and Asia, Smithers supports customers in the transportation, life science, packaging, materials, components, consumer, and energy industries. Smithers delivers accurate data, on time, with high touch, by integrating science, technology, and business expertise, so customers can innovate with confidence.